Cargando…

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing

BACKGROUND: Patients with prostate cancer may present with metastatic or recurrent disease despite initial curative treatment. The propensity of metastatic prostate cancer to spread to the bone has limited repeated sampling of tumor deposits. Hence, considerably less is understood about this lethal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heitzer, Ellen, Ulz, Peter, Belic, Jelena, Gutschi, Stefan, Quehenberger, Franz, Fischereder, Katja, Benezeder, Theresa, Auer, Martina, Pischler, Carina, Mannweiler, Sebastian, Pichler, Martin, Eisner, Florian, Haeusler, Martin, Riethdorf, Sabine, Pantel, Klaus, Samonigg, Hellmut, Hoefler, Gerald, Augustin, Herbert, Geigl, Jochen B, Speicher, Michael R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707016/ https://www.ncbi.nlm.nih.gov/pubmed/23561577 http://dx.doi.org/10.1186/gm434

Ejemplares similares

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
por: Heitzer, Ellen, et al.
Publicado: (2013)

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
por: Ulz, Peter, et al.
Publicado: (2016)

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
por: Mohan, Sumitra, et al.
Publicado: (2014)

Circulating tumor cells and DNA as liquid biopsies
por: Heitzer, Ellen, et al.
Publicado: (2013)

Single circulating tumor cell sequencing for monitoring
por: Auer, Martina, et al.
Publicado: (2013)

The dynamic range of circulating tumor DNA in metastatic breast cancer
por: Heidary, Maryam, et al.
Publicado: (2014)

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
por: Eisner, Florian, et al.
Publicado: (2015)

Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
por: Zhou, Qing, et al.
Publicado: (2020)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
por: Moser, Tina, et al.
Publicado: (2020)

Mapping of balanced chromosome translocation breakpoints to the basepair level from microdissected chromosomes
por: Obenauf, Anna C, et al.
Publicado: (2010)

The potential of liquid biopsies for the early detection of cancer
por: Heitzer, Ellen, et al.
Publicado: (2017)

External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients
por: Szkandera, Joanna, et al.
Publicado: (2013)

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma
por: Heitzer, Ellen, et al.
Publicado: (2013)

Evaluation of Uric Acid as a Prognostic Blood-Based Marker in a Large Cohort of Pancreatic Cancer Patients
por: Stotz, Michael, et al.
Publicado: (2014)

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2019)

Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2020)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
por: Buder, Anna, et al.
Publicado: (2021)

Pre-Treatment Anemia Is a Poor Prognostic Factor in Soft Tissue Sarcoma Patients
por: Szkandera, Joanna, et al.
Publicado: (2014)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X
por: Schulz, Eduard, et al.
Publicado: (2014)

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
por: Stotz, M, et al.
Publicado: (2013)

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer
por: Stotz, M, et al.
Publicado: (2013)

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
por: Perakis, Samantha O, et al.
Publicado: (2020)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial
por: Riedl, Jakob M., et al.
Publicado: (2021)

Genetic and epigenetic analysis of putative breast cancer stem cell models
por: Balic, Marija, et al.
Publicado: (2013)

Desmoid Tumor Treated with Polychemotherapy Followed by Imatinib: A Case Report and Review of the Literature
por: Knechtel, Gudrun, et al.
Publicado: (2010)

Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays
por: Geigl, Jochen B., et al.
Publicado: (2009)

Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
por: Bourrier, Chantal, et al.
Publicado: (2020)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival
por: Gary, T, et al.
Publicado: (2012)

High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
por: Pichler, M, et al.
Publicado: (2013)

Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression
por: Kornfeld, J-W, et al.
Publicado: (2011)

Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
por: Dalpiaz, O, et al.
Publicado: (2014)

Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma
por: Aigelsreiter, A, et al.
Publicado: (2013)

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
por: Suppan, Christoph, et al.
Publicado: (2019)

Risk stratification for venous thromboembolism in patients with testicular germ cell tumors
por: Bezan, Angelika, et al.
Publicado: (2017)

Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
por: Szkandera, J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pf15leeegn16ucugbdcji3ndpr